Optimal Timing of Intratympanic Corticosteroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss: A Mini-Review

ABSTRACT

Idiopathic sudden sensorineural hearing loss (ISSNHL) is an otologic emergency. While systemic corticosteroids are first-line therapy, intratympanic corticosteroid (ITC) injection has emerged as an important modality. The optimal timing of ITC—as primary therapy, combined initial treatment, or salvage therapy—remains controversial. To critically synthesize current evidence regarding ITC efficacy at different treatment timings and provide evidence-based clinical recommendations. A structured search of PubMed, Embase, and the Cochrane Library was conducted from database inception to December 2025 using terms sudden sensorineural hearing loss, ISSNHL, sudden deafness, intratympanic injection, ITC, intratympanic dexamethasone, and intratympanic methylprednisolone. The search identified 321 records, and additional articles were found in the reference lists of key reviews, meta-analyses, and guidelines. Studies were selected using predefined criteria, prioritizing randomized controlled trials, systematic reviews, meta-analyses, clinical practice guidelines, and relevant observational studies in adults with ISSNHL. Eligible studies evaluated ITC as primary monotherapy, combined initial therapy, or salvage therapy, and reported quantitative audiometric outcomes. Exclusion criteria included non-idiopathic sudden hearing loss, pediatric populations, non-corticosteroid intratympanic therapies, animal or laboratory-only studies, case reports, conference abstracts without full text, duplicate publications, and studies without clinically interpretable hearing outcomes. After screening, 25 studies were included. Salvage ITC provides significant benefit (OR: 6.04; 95% CI: 3.26-11.2; NNT≈3) with Grade A evidence. Combined initial therapy is superior to systemic steroids alone (OR: 2.50; 95% CI: 1.95-3.21), particularly for severe hearing loss. ITC monotherapy is non-inferior to systemic steroids (PTA difference: 2.0 dB). A stratified approach based on treatment timing is recommended. Salvage ITC should be offered to all patients with incomplete recovery. Combined therapy should be considered for patients with severe hearing loss. ITC monotherapy is appropriate when systemic steroids are contraindicated.

INTRODUCTION

Idiopathic sudden sensorineural hearing loss (ISSNHL) is defined as the rapid onset of sensorineural hearing impairment of at least 30 dB across three or more contiguous audiometric frequencies, occurring within 72 hours, without an identifiable etiology¹. The reported annual incidence ranges from 5 to 27 per 100,000 population, with approximately 66,000 new cases diagnosed annually in the United States^{1, 2}. ISSNHL represents a true otologic emergency, as delayed treatment is associated with poorer outcomes.

The pathophysiology of ISSNHL remains incompletely understood, with proposed mechanisms including viral infection, vascular compromise, autoimmune injury, and intracochlear membrane rupture³. Despite decades of investigation, no etiology has been identified in over 90% of cases, contributing to ongoing therapeutic controversies.

Corticosteroids have been the mainstay of ISSNHL treatment since Wilson et al.⁴ first demonstrated their efficacy in 1980. Systemic administration—either oral or intravenous—has traditionally been preferred. However, concerns regarding adverse effects, particularly in patients with diabetes mellitus, hypertension, peptic ulcer disease, or psychiatric disorders, have driven interest in alternative delivery methods⁵.

Intratympanic corticosteroid (ITC) injection, first described by Silverstein et al.⁶in 1996, offers theoretical advantages including direct drug delivery to the cochlea via round window membrane diffusion. Pharmacokinetic studies demonstrate that ITC achieves perilymph concentrations 126- to 560-fold higher than systemic administration⁷.

Currently, ITC is employed in three distinct clinical scenarios: (1) as primary monotherapy; (2) as combined initial therapy with systemic steroids; and (3) as salvage therapy following treatment failure. The 2019 AAO-HNS Clinical Practice Guideline provides a strong recommendation for salvage ITC (1), but only optional recommendations for other indications.

This mini-review critically appraises current evidence on the efficacy of ITC at different treatment timings and provides practical, evidence-based recommendations for clinical decision-making.

ITC As Primary Monotherapy

The use of ITC as the sole initial treatment has been investigated as an alternative to systemic corticosteroids, particularly for patients with contraindications to systemic corticosteroids.

Key Clinical Evidence

The landmark study by Rauch et al.⁸ (2011), published in JAMA, was a multicenter randomized noninferiority trial comparing oral prednisone (60 mg/day for 14 days) with intratympanic methylprednisolone (40 mg/mL, four injections) in 250 patients. Results demonstrated that ITC was non-inferior to oral steroids, with mean PTA improvements of 28.7 dB for ITC versus 30.7 dB for oral steroids (difference: 2.0 dB; 95% CI upper bound: 6.6 dB).

Mirian and Ovesen⁹ conducted a systematic review in JAMA Otolaryngology, pooling seven RCTs comparing ITC with systemic steroids. The analysis found no significant differences in PTA gain (MD: 2.01 dB; 95% CI: -5.61 to 1.59) or in complete recovery rates (OR: 0.94; 95% CI: 0.61-1.44).

Tong et al.¹⁰ compared oral, intravenous, and intratympanic methylprednisolone in 90 patients. The ITC group demonstrated the highest response rate (70%) compared with the oral (53.3%) and intravenous (53.3%) groups.

Clinical Implications

Based on available evidence (Grade B), ITC monotherapy is reasonable for patients with contraindications to systemic steroids or who decline systemic therapy. However, Hong et al.¹¹noted oral steroids may provide superior high-frequency recovery, warranting consideration in patients with predominantly high-frequency loss.

Combined Initial Therapy

The rationale for combining ITC with systemic steroids is to achieve synergistic effects by maximizing both local cochlear concentrations and systemic anti-inflammatory activity.

Meta-analytic Evidence

Han et al.¹² conducted a comprehensive meta-analysis of14RCTs involving 1,394 patients. Results strongly favored combined therapy: hearing improvement rate (OR: 2.50; 95% CI: 1.95-3.21), mean PTA improvement (MD:13dB; 95% CI: 9.24-16.77),and speech discrimination improvement (MD:15.72%; 95% CI: 5.11-26.33%).

Li and Ding¹³ performed an updated meta-analysis of 20 RCTs confirming superior outcomes with combined therapy. Subgroup analysis revealed that the benefit was most pronounced with combined therapy at moderate and high doses.

Individual Trial Evidence

Gundogan et al.¹⁴ compared combination therapy with oral steroid alone in 73 patients. Combination therapy resulted in significantly better outcomes (p<0.05), with the greatest benefit observed in patients with severe hearing loss (>70 dB).

Practical Considerations

Combined therapy requires multiple clinic visits (typically 3-4 injections over 1-2 weeks). Current evidence (Grade B+) supports offering combined therapy to patients with moderate-to-severe ISSNHL (≥50 dB) who can accommodate the treatment schedule.

ITC As Salvage Therapy

Salvage therapy is the administration of ITC following failure of initial systemic treatment. This is the most established indication, explicitly recommended by the AAO-HNS guideline with Grade A evidence¹.

Randomized Controlled Trial Evidence

Wu et al.¹⁵ conducted a double-blind, placebo-controlled RCT in 60 patients who failed systemic therapy. The ITC group showed significantly superior outcomes: 44.4% improved by ≥10 dB versus 10.7% in placebo (p<0.05). Mean hearing gain was 9.8±8.5 dB versus 4.5±6.5 dB.

Lee et al.¹⁶ evaluated sequential ITC in 46 non-responders. The treatment group achieved ≥10 dB improvement in 47.6% versus 16.0% in controls (p=0.027).

Meta-analytic Synthesis

The 2022 Cochrane review by Plontke et al.¹⁷ concluded that salvage ITC improves outcomes compared to no treatment. Crane et al.¹⁸ reported an OR of 6.04 (95% CI: 3.26-11.2)—one of the largest effect sizes in ISSNHL literature, translating to NNT≈3.

Optimal Timing

The AAO-HNS guideline recommends initiating salvage ITC 2-6 weeks after onset in patients with incomplete recovery¹. Recent evidence suggests earlier salvage initiation may improve outcomes^{19, 20}.

Evidence Synthesis

Evidence grades were assigned using a modified GRADE-informed framework. Grade A was assigned when evidence was supported by consistent randomized trials, meta-analyses, and guideline recommendations with direct clinical applicability. Grade B was assigned when randomized and meta-analytic evidence was available but was limited by heterogeneity, imprecision, or lack of clear superiority. Grade B + was used as an intermediate category for evidence stronger than typical Grade B evidence but not upgraded to Grade A because of clinical and methodological heterogeneity. Grade C was assigned when recommendations were based mainly on indirect evidence, subgroup data, limited studies, or clinical inference.

Figure 1 presents a clinical decision algorithm that integrates the evidence reviewed above. Table 1 summarizes the quantitative evidence for each timing strategy. Figure 2 presents summary of evidence for ITC timing strategies. Table 1 summarizes the quantitative evidence for each timing strategy. When interpreting the quantitative estimates summarized in Table 1 and Figure 2, readers should consider heterogeneity across the included studies. Treatment protocols varied with respect to corticosteroid type, concentration, injection frequency, number of injections, and treatment timing. Patient populations varied in baseline hearing severity, time from symptom onset to treatment initiation, prior systemic steroid exposure, and comorbidities. Outcome definitions also differed, including PTA improvement, hearing recovery rate, speech discrimination outcomes, and response thresholds such as ≥10 dB hearing gain. Therefore, the summarized effect estimates should be interpreted as evidence of the direction and magnitude of treatment effects, and their clinical application should be guided by treatment timing, baseline hearing severity, patient comorbidities, and the context of the recommendation.

Figure 1.

Clinical decision algorithm for intratympanic corticosteroid therapy in ISSNHL.

ITC: Intratympanic corticosteroids, PTA: Pure tone average, OR: Odds ratio

Table 1. Summary of evidence for ITC timing strategies.

Strategy	Comparator	Effect estimate	Evidence grade
Primary monotherapy	Systemic steroids	PTA diff: 2.0 dB (NS) OR: 0.94 (0.61-1.44)	Moderate (B) Non-inferior
Combined therapy	Systemic alone	OR: 2.50 (1.95-3.21) PTA: +13 dB	Moderate-high (B+) superior
Salvage therapy	No treatment/placebo	OR: 6.04 (3.26-11.2) Response: 44% vs. 11% NNT ≈3	High (A) Strongly recommended

CI: Confidence interval, NNT: Number needed to treat, NS: Not significant, OR: Odds ratio, PTA: Pure tone average

Figure 2.

Summary of evidence for ITC timing strategies (forest plot style representation). Point estimates and confidence intervals from key meta-analyses.

Drug Selection

Both dexamethasone (4-24 mg/mL) and methylprednisolone (40 mg/mL) are widely used. Alharbi et al.²¹ found methylprednisolone may offer slightly higher recovery rates, possibly due to higher sustained perilymphatic concentrations⁷.

Injection Protocols

No standardized protocol exists. Common approaches include 3-4 injections over 2 weeks, daily injections for 3-5 days, or weekly injections. Liebau et al.²² found no clear relationship between frequency and outcomes, suggesting total drug exposure may be more important.

Safety and Tolerability

ITC has a favorable safety profile. Common transient effects include otalgia (10-30%), vertigo (5-15%), and, rarely, tinnitus exacerbation. Rare complications include persistent tympanic membrane perforation (<2%) and otitis media (<1%). The absence of systemic effects is advantageous for patients with comorbidities. Huang et al.²³ demonstrated comparable hearing outcomes with fewer adverse effects for ITC versus systemic administration.

Clinical Recommendations

Clinical recommendation grades in Table 2 were derived from the evidence grades summarized in Table 1 and from the same modified GRADE-informed framework, with additional consideration of treatment effect, safety, patient subgroups, and clinical applicability. Table 2 provides practical recommendations stratified by clinical scenario.

Table 2. Clinical recommendations for ITC Therapy in ISSNHL.

Clinical scenario	Recommended approach	Grade
Standard presentation	Systemic steroids OR combined therapy. Salvage ITC if incomplete recovery at 2 weeks.	B
Severe loss (≥70 dB)	Combined therapy strongly recommended. Aggressive early intervention.	B+
Contraindication to systemic steroids	ITC as primary monotherapy. Non-inferior to systemic.	B
Incomplete recovery after systemic	Salvage ITC (within 2-6 weeks). Strongest evidence.	A
Diabetes mellitus	ITC preferred. Eliminates glycemic perturbations.	C
High-frequency loss	Consider systemic steroids for better high-frequency recovery.	C

ITC: Intratympanic corticosteroids, OR: Odds ratio

Future Directions

Key research priorities include the following: (1) comparative effectiveness trials, such as the ongoing UK STARFISH trial²⁴; (2) identification of predictive biomarkers; (3) protocol standardization; (4) novel delivery systems, including sustained-release formulations²⁵; and (5) long-term outcome data.

Clinical and Research Consequences

ITC has become an essential component of ISSNHL management. Evidence supports a stratified approach: salvage ITC after failed systemic therapy has Grade A evidence (OR: 6.04; NNT≈3). Combined initial therapy is superior to systemic steroids alone (Grade B+, OR: 2.50). ITC monotherapy is non-inferior to systemic steroids (Grade B).

Clinical decision-making should integrate hearing loss severity, comorbidities, patient preferences, and logistical feasibility. As ongoing trials report findings and delivery technologies advance, our understanding will continue to improve.